Quality of life of schizophrenic patients on medications and implications for new drug trials.

摘要: The quality of life schizophrenic patients participating in clinical trials new neuroleptics is rarely systematically assessed. Factors that may have contributed to the neglect such assessments include difficulty measuring changes affecting during short-term and continued belief patients' self-reports about inner states are unreliable. A model determinants specifically related would symptoms, side effects neuroleptics, psychosocial performance. In view importance assessing on medications, author recommends regulatory agencies require neuroleptics.